Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mitochondrial toxicity of antiviral drugs

Abstract

Long-term treatment with antiviral nucleoside analogue drugs, such as AZT, can give rise to delayed and at times severe mitochondrial toxicity. Although these toxic effects are manifest in many tissues, a common disease mechanism can explain the diverse clinical events. A better understanding of these disorders will shed light on genetic mitochondrial diseases and lead to the design of safer and more effective antiviral drugs.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Luft, R. The development of mitochondrial medicine. Proc.natn. Acad. Sci. 91, 8731–8738 (1994).

    Article  CAS  Google Scholar 

  2. 2

    Wallace, D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256, 628–632 (1994).

    Article  Google Scholar 

  3. 3

    Elion, G.B. Discovery, mechanism of action, and selectivity. J. med. Virol, (supp 1) 1, 2–6 (1993).

    Article  Google Scholar 

  4. 4

    McGowan, J.J. et al. Overview of the preclinical development of an antiretroviral drug, 2′,3′-dideoxyinosine. Rev. infect. Dis. 12, S513–S521 (1990).

    Article  CAS  Google Scholar 

  5. 5

    Prusoff, W., Lin, T.-S., Pivazyan, A., Sun, A.S. & Birks, E. Empirical and rational approaches for development of inhibitors of the human immunodeficiency virus-HIV-1. Pharmac. Ther. 60, 315–329 (1993).

    Article  CAS  Google Scholar 

  6. 6

    Mitsuya, H., Yarchoan, R. & Broder, S. Molecular targets for AIDS therapy. Science 249, 1533–1544 (1990).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. 7

    Dalakas, M.C., Illa, I., Pezeshkpour, G., Laukaitis, J., Cohen, B. & Griffin, J. Mitochondrial myopathy caused by long term zidovudine therapy. New Engl. J. Med. 322, 1098–1105 (1990).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. 8

    Lewis, W., Simpson, J.F. & Meyer, R.R. Cardiac mitochondrial DNA polymerase-γ is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circulation Res 74, 344–348 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. 9

    Cui, L., Toon, S., Schinazi, R.F. & Sommadossi, J.-P. Cellular and molecular events leading to mitochondrial toxicity of 1-[2′-deoxy-2′-fluoro-β-D-arabino-furanosyl]-5-iodouracil in human liver cells. J. clin. Invest. 95, 555–563 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    Brahams, D. Deaths in US fialuridine trial. Lancet 343, 1494–1495 (1994).

    Article  CAS  PubMed  Google Scholar 

  11. 11

    Marshall, E. Drug trial deaths deemed unavoidable. Science 264, 1530 (1994).

    Article  CAS  PubMed  Google Scholar 

  12. 12

    Macilwain, C. US health agencies at odds over trial deaths. Nature 369, 433 (1994).

    Article  CAS  PubMed  Google Scholar 

  13. 13

    Rozencweig, M. et al. Overview of phase 1 trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. infect. Dis. 12, S570S575 (1990).

    Article  Google Scholar 

  14. 14

    Butler, K.M. et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. New Engl. J. Med. 324, 137–144 (1993).

    Article  Google Scholar 

  15. 15

    Freiman, J.P., Helfert, K.E., Hamrell, M.R. & Stein, D.S. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7, 379–385 (1993).

    Article  CAS  PubMed  Google Scholar 

  16. 16

    d'Amati, G., Kwan, W. & Lewis, W. Dilated cardiomyopathy in a zidovudine treated AIDS patient. Cardiovasc. Pathol. 1, 317–320 (1992).

    Article  CAS  PubMed  Google Scholar 

  17. 17

    Chang, C.-N., Skalski, V., Zhou, J.H. & Cheng, Y-C. Biochemical pharmacology of (+)- and (−)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. biol. Chem. 267, 22414–22420 (1992).

    CAS  PubMed  Google Scholar 

  18. 18

    Reichard, P. Interactions between deoxyribonucleotide and DNA. Annu. Rev. Biochem. 57, 349–374 (1988).

    Article  CAS  PubMed  Google Scholar 

  19. 19

    Munch-Petersen, B., Cloos, L., Tyrsted, G. & Eriksson, S. Diverging substrate specificity of pure human thymidine kinase 1 and 2 against antiviral dideoxynucleosides. J. biol. Chem. 266, 9032–9038 (1991).

    CAS  PubMed  Google Scholar 

  20. 20

    Fry, M. & Loeb, L.A. Animal Cell DNA Pofymerases 221 (CRC Press, Boca Raton, Florida, 1986).

    Google Scholar 

  21. 21

    Wang, T.S.F. Eukaryotic DNA polymerases. Annu. Rev. Biochem. 60, 513–552 (1991).

    Article  CAS  PubMed  Google Scholar 

  22. 22

    Wallace, D.C. Diseases of the mitochondrial DNA. Annu. Rev. Biochem. 61, 1175–1212 (1992).

    Article  CAS  PubMed  Google Scholar 

  23. 23

    Wallace, D.C. Mitochondrial DNA sequence variation in human evolution and disease. Proc. natn. Acad. Sci. U. S. A. 91, 8739–8746 (1994).

    Article  CAS  Google Scholar 

  24. 24

    Wright, G.E. & Brown, N.C. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmac. Ther. 47, 447–497 (1990).

    Article  CAS  Google Scholar 

  25. 25

    Dixon, M. & Webb, E.C. Enzymes 3rd edn. (Academic, New York, 1979).

    Google Scholar 

  26. 26

    Richmann, D.D. et al. The toxicity of AZT in the treatment of patients with AIDS and AIDS-related complex. New Engl. J. Med. 317, 192–197 (1987).

    Article  Google Scholar 

  27. 27

    Yarchoan, R., Mitsuya, H., Myers, C.E. & Broder, S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. New Engl. J. Med. 321, 726–738 (1989).

    Article  CAS  PubMed  Google Scholar 

  28. 28

    Nickel, W., Austermann, S., Bialek, G. & Grosse, F. Interactions of azidothymidine triphosphate with the cellular DNA polymerases α, β, and and with DNA Primase. J. biol. Chem. 267, 848–854 (1992).

    CAS  PubMed  Google Scholar 

  29. 29

    Dainiak, N., Worthington, M., Riordan, M.A., Kreczko, S. & Goldman, L. 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br. J. Haematol. 69, 299–304 (1988).

    Article  CAS  PubMed  Google Scholar 

  30. 30

    Scadden, D.T., Zon, L.I. & Groopman, J.E. Pathophysiology and management of HIV-associated hematologic disorders. Blood 74, 1455–1463 (1989).

    Article  CAS  Google Scholar 

  31. 31

    Hamburger, A.W. & Chen, R.-B. Amelioration of azidothymidine-induced erythroid toxicity by hemin and stem cell factor in immune-suppressed mice. Exp. Hematol. 22, 348–352 (1994).

    CAS  PubMed  Google Scholar 

  32. 32

    Yoshida, Y. & Yoshida, C. Reversal of azidothymidine-induced bone marrow suppression by 2′,3′-dideoxythymidine as studied by hemopoietic clonal culture. AIDS Res. hum. Retrovir. 6, 929–932 (1990).

    Article  CAS  Google Scholar 

  33. 33

    Falcone, A., Darnowski, J.W., Ruprecht, R.M., Chu, S.H., Brunetti, I. & Calabresi, P. Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. Blood 76, 2216–2221 (1990).

    Article  CAS  Google Scholar 

  34. 34

    Rötig, A. et al. Pearson's marrow-pancreas syndrome. J. clin. Invest. 86, 1601–1608 (1990).

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35

    Arnaudo, E., Dalakas, M.C., Shanske, S., Moraes, C.T., DiMauro, S. & Schoen, E.A. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337, 508–510 (1991).

    Article  CAS  Google Scholar 

  36. 36

    Pezeshkpour, G., Illa, I. & Dalakas, M.C. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. Hum. Pathol. 22, 1281–1288 (1991).

    Article  CAS  Google Scholar 

  37. 37

    Lewis, W., Chomyn, A., Gonzalez, B. & Papoian, T. Zidovudine induces molecular, biochemical and Ultrastructural changes in rat skeletal muscle mitochondria. J. clin. Invest. 89, 1354–1360 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. 38

    Lewis, W. et al. Mitochondrial Ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest. 65, 228–236 (1991).

    CAS  PubMed  Google Scholar 

  39. 39

    Lamperth, L., Dalakas, M.C., Dagani, F., Anderson, J. & Ferrari, R. Abnormal skeletal and cardiac mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest. 65, 742–751 (1991).

    CAS  PubMed  Google Scholar 

  40. 40

    Dalakas, M.C. Carnitine loss and AZT-myopathy. Ann. Neurol. 36, 680–681 (1994).

    Article  Google Scholar 

  41. 41

    Chariot, P. & Gherardi, R. Partial cytochrome c oxidase deficiency and cyto-plasmic bodies in patients with zidovudine myopathy. Neuromusc. Dis. 5, 357–363 (1991).

    Article  Google Scholar 

  42. 42

    Chariot, P. et al. Blood lactate/pyruvate ratio is a non invasive test for the diagnosis of zidovudine myopathy. Arthritis Rheumat. 37, 583–586 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    Weissman, J.D., Constantinides, I., Hudgins, P. & Wallace, D.C. 31P magnetic resonance spectroscopy suggests impaired mitochondrial functions in AZT-treated HIV-infected patients. Neurology 42, 619–623 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Dalakas, M.C., Monzon, M.E., Bernardini, I., Gahl, W.A. & Jay, C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 35, 483–487 (1994).

    Article  Google Scholar 

  45. 45

    Mhiri, C. et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol 29, 606–614 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. 46

    Peters, R.S., Winer, J., Landon, D.N., Stotter, A. & Pinching, A.J. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q. J. Med. 86, 5–15 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47

    Jay, C., St Dalakas, M.C. Myopathies and neuropathies in HIV-infected adults and children. in Pediatric Aids (Williams & Wilkins, Baltimore, 1994)

    Google Scholar 

  48. 48

    Semino-Mora, M.C., Leon-Monzon, M.E. & Dalakas, M.C. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part 1: L-Carnitine prevents the myotoxicity of AZT in vitro. Lab. Invest. 70, 102–112 (1994).

    Google Scholar 

  49. 49

    d'Amati, G. & Lewis, W. Zidovudine azidothymidine causes early increases in mitochondrial ribonucleic acid abundance and induces Ultrastructural changes in cultured mouse muscle cells. Lab. Invest. 71, 879–884 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50

    Herskowitz, A., Willoughby, S.B., Baughman, K.L., Schulman, S.P. & Bartlett, J.D. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of 6 cases. Ann. intern. Med. 116, 311–313 (1992).

    Article  CAS  PubMed  Google Scholar 

  51. 51

    Lipschultz, S.E., Gray, J., Sanders, S.P., Hale, A.R., Mclntosh, K. & Colan, S.D. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. New Engl. J. Med. 327, 1260–1265 (1992).

    Article  Google Scholar 

  52. 52

    Chatta, G., Arieff, A.I., Cummings, C. & Tierney, L.M. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann. intern. Med. 118, 37–39 (1993).

    Article  Google Scholar 

  53. 53

    Jolliet, P. & Widman, J.J. Reye's syndrome in adult with AIDS. Lancet 335, 1457 (1990).

    Article  CAS  PubMed  Google Scholar 

  54. 54

    Dubinsky, R.M., Yarchoan, R., Dalakas, M.C. & Broder, S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 12, 856–860 (1989).

    Article  CAS  PubMed  Google Scholar 

  55. 55

    Anderson, T.D. et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab Invest. 70, 724–739 (1994).

    CAS  PubMed  Google Scholar 

  56. 56

    Jay, C., Ropka, M. & Dalakas, M.C. The drugs 2′,3′-dideoxyinosine (ddl) and 2′,3′-dideoxycytidine (ddC) are safe alternatives in people with AIDS with, zidovudine-induced myopathy. J. AIDS 7, 630–631 (1994).

    CAS  Google Scholar 

  57. 57

    Chen, C-H. & Cheng, Y-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-deoxythymidine. J. biol. Chem. 264, 11934–11937 (1989).

    CAS  PubMed  Google Scholar 

  58. 58

    Keilbaugh, S.A., Prusoff, W.H. & Simpson, M.V. The PC 12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs. Biochem. Pharmacol. 42, R5–R8 (1991).

    Article  CAS  PubMed  Google Scholar 

  59. 59

    Fourel, I., Li, J., Hantz, O., Jacquet, C., Fox, J.J. & Trepo, C. Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J. med. Virol. 37, 122–126 (1992).

    Article  CAS  PubMed  Google Scholar 

  60. 60

    Lewis, W., Simpson, J.F., Meyer, R.R., Colacino, J.M. & Perrino, F.W. Mammalian DNA polymerases α, β, γ, δ, and incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphos-phate. Biochemistry 33, 14620–14624 (1994).

    Article  CAS  PubMed  Google Scholar 

  61. 61

    Richardson, F.C., Engelhardt, J.A. & Bowsher, R.R. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc. natn. Acad. Sci. U. S. A. 91, 12003–12007 (1994).

    Article  CAS  Google Scholar 

  62. 62

    Moraes, C.T. et al. mtDNA depletion with variable tissue expression: an novel genetic abnormality in mitochondrial diseases. Am. J. hum. Genet. 48, 492–501 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Progress in Neuropathy Vol 7 (eds. Sato, T. & DiMauro, S.) (Raven Press, New York, 1991).

  64. 64

    Morgan-Hughes, J.A. Mitochondrial diseases. in Myology (eds. Engel, A. G. & Franzini-Armstrong, C.) 1610–1660 (McGraw Hill, New York, 1994).

    Google Scholar 

  65. 65

    Shoffner, J.M.V.I. & Wallace, D.C. Oxidative phosphorylation diseases. Disorder of two genomes. Adv. hum. Genet. 19, 267–330 (1990).

    Article  CAS  PubMed  Google Scholar 

  66. 66

    Moraes, C.T. et al. Mitochondrial DNA in human pathology, (eds. DiMauro, S. & Wallace, D. C.) 97–108 (Raven, New York, 1993).

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lewis, W., Dalakas, M. Mitochondrial toxicity of antiviral drugs. Nat Med 1, 417–422 (1995). https://doi.org/10.1038/nm0595-417

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing